$ANRO earnings report

Alto Neuroscience reports Q3 2026 net loss of $25.1 million, up from $14.2 million, with R&D up to $18.2 million; cash of $319.8 million expected to fund operations through 2030. AlphAI read Alto Neuroscience's Q3 FY2026 filing as mixed.

Q3 FY2026

AlphAI · Earnings readANRO · Q3 2026 · ended 2026-09-30

Alto Neuroscience reports Q3 2026 net loss of $25.1 million, up from $14.2 million, with R&D up to $18.2 million; cash of $319.8 million expected to fund operations through 2030

→Mixed quarter

The filing reports no revenue. Operating costs and the net loss rose sharply year over year as the ALTO-207 PACE program and headcount expanded. Balance sheet strength improved after a $100.0 million July 2026 financing, and the company reiterated its pipeline milestone timing. The filing contains no financial guidance, so the read rests on spending growth, cash runway and milestone delivery.

EPS · GAAP
$(0.54)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development expenses, Q3 2026GAAP$18.2 million (Q3 2026); $18,161 thousand in statement of operations––
General and administrative expenses, Q3 2026GAAP$9.1 million (Q3 2026); $9,064 thousand in statement of operations––
Total operating expenses, Q3 2026GAAP$27.23M––
Loss from operations, Q3 2026GAAP−$27.23M––
Interest income, Q3 2026GAAP$2.6M––
Interest expense, Q3 2026GAAP−$463K––
Other, net, Q3 2026GAAP−$36K––
Total other income, net, Q3 2026GAAP$2.10M––
Net loss, Q3 2026GAAP$(25.1) million; $(25,124) thousand in statement of operations––
Comprehensive loss, Q3 2026GAAP−$25.12M––
Net loss per share, basic and diluted, Q3 2026GAAP$(0.54)––
Research and development expenses, nine months 2026GAAP$60.56M––
General and administrative expenses, nine months 2026GAAP$22.93M––
Total operating expenses, nine months 2026GAAP$83.49M––
Loss from operations, nine months 2026GAAP−$83.49M––
Interest income, nine months 2026GAAP$6.27M––
Interest expense, nine months 2026GAAP−$1.50M––
Loss on debt extinguishment, nine months 2026GAAP— (no amount printed for 2026)––
Other, net, nine months 2026GAAP−$281K––
Total other income, net, nine months 2026GAAP$4.49M––
Net loss, nine months 2026GAAP−$79.00M––
Comprehensive loss, nine months 2026GAAP−$79.00M––
Net loss per share, basic and diluted, nine months 2026GAAP$(1.87)––
Cash, cash equivalents and restricted cash, September 30, 2026GAAP$319.8 million; $319,844 thousand––
Total assets, September 30, 2026GAAP$326.5M––

Capital returns

  • No share repurchases or dividends are reported in the filing.
  • July 2026 underwritten registered direct offering of 3,776,436 shares of common stock at $26.48 per share, gross proceeds of $100.0 million and net proceeds of approximately $94.6 million. Proceeds are intended to accelerate and expand ALTO-207 development, including PACE-3, and for general working capital.

What drove it

  • Company states the R&D increase was primarily driven by costs associated with the ALTO-207 PACE program.
  • Company states the G&A increase was primarily due to increased headcount and related personnel costs.
  • Company states the increase in cash since December 31, 2025 follows the $100 million financing completed in July 2026.
  • Interest income rose to $2,600 thousand from $1,532 thousand in Q3 2026 versus Q3 2025, as printed; the filing does not state a cause.

Concerns

  • Net loss widened to $25.1 million from $14.2 million, and nine-month net loss reached $(78,999) thousand versus $(47,056) thousand.
  • Operating expenses rose in both the quarter and the nine months, with R&D and G&A both up year over year.
  • Net loss per share is $(0.54) versus $(0.52) in the prior year quarter, while weighted-average shares rose to 46,531 thousand from 27,104 thousand, reflecting the July 2026 offering.
  • Milestone timing is largely in 2027. PACE-1 topline is expected in 2H 2027, and the FDA interaction outcome and Phase 1 data are expected in late 2026 or early 2027 and remain subject to FDA feedback.
  • The filing states that trials may have unsatisfactory outcomes and that the company's cash runway projections may prove inaccurate, as listed among its forward-looking risk factors.

What to watch

  • Outcome of the ALTO-207 FDA interaction and Phase 1 modified-release formulation data, expected late 2026 or early 2027.
  • Initiation of the PACE-2 Phase 3 adjunctive TRD trial, expected early 2027 pending FDA alignment on design.
  • ALTO-300 Phase 2b MDD topline data, expected 1H 2027, and ALTO-100 Phase 2b BPD topline data, expected mid-2027.
  • PACE-1 Phase 2b adjunctive TRD topline data, expected 2H 2027, and PACE-3 Phase 3 monotherapy initiation, expected 2H 2027.
  • Trajectory of R&D and G&A expense in coming quarters, and whether the company's expectation of funding operations through 2030 holds.

Balance sheet and cash flow

  • Cash, cash equivalents and restricted cash: $319.8 million (September 30, 2026) versus $177.0 million (December 31, 2025) as reported.
  • Total assets: $326,505 thousand (September 30, 2026) versus $184,689 thousand (December 31, 2025).
  • Total liabilities: $29,975 thousand (September 30, 2026) versus $33,547 thousand (December 31, 2025).
  • Accumulated deficit: $(280,633) thousand (September 30, 2026) versus $(201,634) thousand (December 31, 2025).
  • The company expects its cash to fund planned operations through 2030. No operating or free cash flow figures are reported.

Analysis

Alto Neuroscience reported no revenue for the quarter ended September 30, 2026. The results are a function of development spending. Research and development expenses were $18.2 million versus $10.5 million a year earlier, and general and administrative expenses were $9.1 million versus $4.4 million. The company attributes the R&D increase primarily to costs of the ALTO-207 PACE program and the G&A increase primarily to higher headcount and related personnel costs. Total operating expenses were $27,225 thousand against $14,951 thousand, and the loss from operations followed the same path. Net loss reached $25.1 million versus $14.2 million, and net loss per share was $(0.54) versus $(0.52). Net other income of $2,101 thousand, which includes interest income of $2,600 thousand, partly offset the operating loss but did not change its direction.

For the nine months, research and development expenses were $60,563 thousand versus $33,623 thousand and general and administrative expenses were $22,929 thousand versus $15,686 thousand. The nine-month net loss was $(78,999) thousand against $(47,056) thousand, and nine-month net loss per share was $(1.87) versus $(1.74). The step-up in spending is therefore present across the year to date, not only in the quarter.

The balance sheet changed materially in 2026. Cash, cash equivalents and restricted cash rose to $319.8 million at September 30, 2026 from $177.0 million at December 31, 2025, after the July 2026 registered direct offering of 3,776,436 shares at $26.48 per share, which generated gross proceeds of $100.0 million and net proceeds of approximately $94.6 million. Total assets were $326,505 thousand and total liabilities were $29,975 thousand. The accumulated deficit increased to $(280,633) thousand from $(201,634) thousand. Management states that cash is expected to fund planned operations through 2030. The filing gives no operating or free cash flow figures, so the runway claim cannot be tested against cash generation in the document.

Operationally, the filing emphasizes timing. ALTO-207 PACE-1 topline data are expected in 2H 2027, PACE-2 is planned to start in early 2027 pending FDA alignment, and PACE-3 is expected to start in 2H 2027. ALTO-300 and ALTO-100 Phase 2b topline data are expected in 1H 2027 and mid-2027. The filing describes the Phase 1 modified-release formulation results and blinded PACE-1 safety data as expected by early 2027, with the FDA interaction outcome to follow. Forward-looking statements caution that trial outcomes may be unsatisfactory and that spending needs may exceed current plans. The filing contains no financial guidance, so there is no prior outlook to compare against this quarter.

Management, verbatim

PACE-1 remains on track, and our recent financing has enabled us to expand the ALTO-207 Phase 3 development plans to include both monotherapy and adjunctive trials, aimed at supporting a broad label in TRD.

Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience

Not in the filing

stated, not guessed
  • Revenue: the filing reports no revenue line; none is available for any period.
  • Gross margin, cost of sales and tax rate: not reported in the filing.
  • Financial guidance for 2026 or later periods: not provided in this filing.
  • Previous release outlook: not provided, so vs_prior_guidance cannot be assessed.
  • Prior-year and prior-quarter percentage changes for operating expense, loss and per-share lines: the filing does not print them.
  • Prior-year comparison for cash, cash equivalents and restricted cash and total assets: the only comparator printed is December 31, 2025, not the same period of the prior year.
  • Operating cash flow, investing cash flow and free cash flow: not reported.
  • Total equity: not printed; only total assets, total liabilities and accumulated deficit are given.
  • Share repurchases and dividends: none reported.
  • Segment information: none reported; the company presents a single business.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about ANRO earnings dates

When is Alto Neuroscience's next earnings date?
AlphAI has no date for ANRO yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.